Seeking Alpha

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and ...

Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (PALI ...
Seeking Alpha

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Phase 1b data demonstrated 100% clinical response and promising signals regarding the efficacy of PALI-2108 in ulcerative colitis (UC) using FDA-defined endpoints Biomarker analyses showed ...
Nasdaq

Palisade Bio Reports Positive Preliminary Data for PALI-2108 in Phase 1a/b Trial for Ulcerative Colitis

Palisade Bio, Inc. announced positive preliminary findings from its ongoing Phase 1a/b clinical study of PALI-2108, a treatment for Ulcerative Colitis (UC), indicating high tolerability and safety ...